| 1 | Consumer Staples | XLP | +3.8% |
| 2 | Utilities | XLU | +1.6% |
| 3 | Real Estate | XLRE | +1.0% |
| 4 | Healthcare | XLV | -1.0% |
| 5 | Financials | XLF | -2.6% |
| 6 | Consumer Disc. | XLY | -2.7% |
| 7 | Materials | XLB | -5.8% |
| 8 | Industrials | XLI | -7.1% |
| 9 | Communication | XLC | -8.2% |
| 10 | Energy | XLE | -11.2% |
| 11 | Technology | XLK | -21.0% |
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. …
| Quarter | Date | EPS est. | Actual | Surprise | YoY | Rev. est. | Actual | Surprise | YoY | Copy |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3 '26 | 11/9/264:00 PM | -$0.63 | -$0.63GAAP | 0.0% | -15% | — | $0 | — | — | |
| Q2 '26 | 8/10/267:03 AM | -$0.50 | -$0.55GAAP | -10.0% | -20% | — | $0 | — | — | |
| Q1 '26 | 5/13/264:00 PM | -$0.53 | -$0.48GAAP | +9.4% | -20% | — | $0 | — | — | |
| Q4 '25 | 3/12/264:05 PM | -$0.61 | -$0.45GAAP | +26.2% | +8% | — | $0 | — | — | |
| Q3 '25 | 11/12/254:00 PM | -$0.54 | -$0.55GAAP | -1.9% | +62% | — | $0 | — | — | |
| Q2 '25 | 8/11/259:03 AM | -$0.45 | -$0.46GAAP | -2.2% | ⚠ Check | — | $0 | — | — | |
| Q1 '25 | 5/14/254:15 PM | -$0.49 | -$0.40GAAP | +18.4% | n/m | — | $0 | — | — |
⚠ Potential error in calculation, check manually. The two EPS figures may be on different share counts (a stock split one source has not adjusted for).
n/m = not meaningful: one EPS figure is from around the IPO, before preferred stock converted and the share count settled, so the two are on different share counts.
GAAP = diluted EPS as filed with the SEC.